Human Oncology & Pathogenesis Program

The Sarat Chandarlapaty Lab

Sarat Chandarlapaty, MD, PhD

Nadissy Foundation Endowed Chair in Breast Cancer Research

My lab focuses on understanding the regulation of growth factor signal transduction pathways that are aberrantly activated in cancers, with a focus on those implicated in breast cancer pathogenesis.

View Lab Overview

Publications Highlights

Li Q, Jiang B, Guo J, Shao H, Del Priore IS, Chang Q, Kudo R, Li Z, Razavi P, Liu B, Boghossian AS, Rees MG, Ronan MM, Roth JA, Donovan KA, Palafox M, Reis-Filho JS, de Stanchina E, Fischer ES, Rosen N, Serra V, Koff A, Chodera JD, Gray NS, Chandarlapaty S. INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. Cancer Discov. 2022 Feb;12(2):356-371. doi: 10.1158/2159-8290.CD-20-1726. Epub 2021 Sep 20.

Smith AE, Ferraro E, Safonov A, Morales CB, Lahuerta EJA, Li Q, Kulick A, Ross D, Solit DB, de Stanchina E, Reis-Filho J, Rosen N, Arribas J, Razavi P, Chandarlapaty S. HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nat Commun. 2021 Nov 18;12(1):6667. doi: 10.1038/s41467-021-27093-y.

Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, Vasan N, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, Cowan AM, Comen E, Singh A, Covey A, Berger MF, Hudis CA, Norton L, Nagy RJ, Odegaard JI, Lanman RB, Solit DB, Robson ME, Lacouture ME, Brogi E, Reis-Filho JS, Moynahan ME, Scaltriti M, Chandarlapaty S. (2020). Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat Cancer, Mar;1(4):382–393.

Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho JS, Chandarlapaty S. (2018). Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell, Dec;34(6):893-905.

Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, Huang X, Monian P, Jiang X, de Stanchina E, Baselga J, Liu N, Chandarlapaty S*, Rosen N.* (2014). Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov, Mar;4(3):334-47.

View All Publications

People

Sarat Chandarlapaty, MD, PhD

Nadissy Foundation Endowed Chair in Breast Cancer Research

Physician-scientist Sarat Chandarlapaty studies the regulation of growth factor signaling networks in cancer.
MD, Wake Forest School of Medicine
PhD, University of North Carolina

[email protected]: Email Address
View physician profile: Physician profile

Members

Wanyi Chen

WGS Student

Payal Patel

Graduate Student

Lab Alumni

Bo Liu, Research Associate — Bo Liu
Research Associate

Ramya Segu Rajappachetty
Research Technician Sr.

ChengCheng Yang
Graduate Research Assistant

Lab Affiliations

Achievements

Clinical Investigator Award, Damon Runyon Cancer Research Foundation (2012)

Young Investigator Award, American Society of Clinical Oncology (2007)

Fellow in Biomedical Research, The Dana Foundation (2006)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

[email protected]

Lab Head Email
Lab Twitter

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Sarat Chandarlapaty discloses the following relationships and financial interests:

Boxer Capital, LLC
Professional Services and Activities
Eli Lilly and Company
Professional Services and Activities
Encore Medical Education
Professional Services and Activities
Genesis Therapeutics
Professional Services and Activities
Gerson Lehrman Group
Professional Services and Activities
Novartis
Professional Services and Activities

Nuvalent, Inc.
Professional Services and Activities
Odyssey Biosciences
Equity; Fiduciary Role / Position; Intellectual Property Rights
Prelude Therapeutics
Professional Services and Activities
SAGA Diagnostics
Professional Services and Activities
Totus Medicines Inc.
Equity
eFFECTOR Therapeutics
Equity; Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures

Changing how the world understands and treats cancer

Training the next generation of clinicians and scientists

We’re here for you.

Make an appointment

Speak to a care advisor

Partner with us to treat your patient’s cancer.

CALL OUR DEDICATED CLINICIAN ACCESS NUMBER

We treat every type of cancer, including the most important one: yours.

Our mission: Ending cancer for life.

In the U.S.

Outside of the U.S.